ANI Pharmaceuticals vs Tilray Brands
Tilray Brands reported revenue of $916 million in fiscal 2026, about the same as ANI Pharmaceuticals' $883 million in fiscal 2025. ANI Pharmaceuticals' revenue grew 43.8% in its latest year, and Tilray Brands' grew 11.5%. ANI Pharmaceuticals had an operating margin of 12.6%, against -6.9% at Tilray Brands. Their fiscal years end in different months (December 31 and May 31), so the periods don't line up exactly.
Side by side
| ANI Pharmaceuticals | Tilray Brands | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, May 31, 2026 |
| Revenue | $883M | $916M |
| Revenue growth | 43.8% | 11.5% |
| Revenue growth a year, last 5 years | 33.5% | 12.3% |
| Gross margin | — | 28.4% |
| Operating margin | 12.6% | −6.9% |
| Net margin | 8.9% | −13.3% |
| Free cash flow | $171M | — |
| Free cash flow margin | 19.4% | — |
| Return on capital | 15.9% | −3.4% |
| Net debt to EBITDA | 0.1x | — |
| Dividends and buybacks | $13M | $0M |
| Change in diluted share count | 9.9% | 25.6% |
| Last close | $69.13 | $2.07 |
| P/E at the last close | 13.8× | — |
| Insider trades, last 12 months | sold $13.6 million | bought $69,225, sold $232,879 |
| Piotroski F-score | 6 of 8 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ANI PharmaceuticalsTilray Brands
Operating margin
Percent of revenue
ANI PharmaceuticalsTilray Brands
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ANI PharmaceuticalsTilray Brands
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ANI Pharmaceuticals and Tilray Brands pages.